Searching…
AUSTEDO XR ® (deutetrabenazine) extended-release tablets and AUSTEDO ® (deutetrabenazine) tablets are indicated in adults for the treatment of chorea associated with Huntington’s disease and for the treatment of tardi...
Once-daily AUSTEDO XR® (deutetrabenazine) extended release tablets reduce uncontrollable Tardive Dyskinesia (TD) body movements. See safety info including Boxed Warning.
2.1 Dosing Information The dose of AUSTEDO XR and AUSTEDO is determined individually for each patient based on reduction of chorea or tardive dyskinesia and tolerability. Table 1 displays the recommended dosage and im...
The most common adverse reactions for AUSTEDO (4% and greater than placebo) in controlled clinical studies in patients with tardive dyskinesia were nasopharyngitis and insomnia. Adverse reactions with AUSTEDO XR exten...
Austedo's drug class is a VMAT2 inhibitor (vesicular monoamine transporter 2 inhibitor). Austedo tablets are taken twice daily, and the Austedo XR (extended-release) tablets are taken once daily. What is Tardive dyski...
Austedo standard and XR tablets are currently indicated for adults for the treatment of chorea in Huntington disease and tardive dyskinesia. Austedo is the first VMAT2 inhibitor approved by the US Food and Drug Admini...
Teva Pharmaceuticals has announced new real-world data showing that AUSTEDO (deutetrabenazine) tablets and AUSTEDO XR (extended-release) tablets led to meaningful improvements for adults living with tardive dyskinesia...
Parkinsonism: AUSTEDO XR and AUSTEDO may cause parkinsonism in patients with Huntington’s disease or tardive dyskinesia. Parkinsonism has also been observed with other VMAT2 inhibitors.
AUSTEDO® XR (deutetrabenazine) extended-release tablets is the first medication approved to treat both tardive dyskinesia and Huntington's disease chorea. See safety info including Boxed Warning.
Austedo (aw-STED-oh) was approved in 2017 and is the first medicine approved to treat both tardive dyskinesia and chorea caused by Huntington’s disease.
